Type B insulin resistance syndrome associated with systemic lupus erythematosus.
OBJECTIVE
To document a case of type B insulin resistance syndrome associated with systemic lupus erythematosus.


METHODS
We present the clinical course of a female patient with type B insulin resistance syndrome, from the onset, diagnosis, and empiric treatment until remission of her disease.


RESULTS
A 40-year-old African American woman with systemic lupus erythematosus presented with a relatively acute onset of severe hyperglycemia in January 2004. Her hyperglycemia was resistant to treatment with high doses of insulin (up to an equivalent dose of regular insulin of 4,500 units daily). The diagnosis of type B insulin resistance syndrome was confirmed after her insulin receptor antibody was found to be strongly positive. The patient's hemoglobin Ale level improved substantially after she had been treated with azathioprine for 3 months. By November 2004, she was able to discontinue insulin therapy. Repeated insulin receptor antibody testing in February 2005 revealed that her insulin receptor antibody had become negative. The patient's fasting glucose level became normal, and only occasional mild postprandial hyperglycemic episodes have been noted.


CONCLUSIONS
Immunosuppressive therapy with azathioprine seems to be responsible for our patient's remission of type B insulin resistance, although the possibility of the occurrence of a spontaneous remission cannot be completely excluded.
Bao
Shichun
S
Division of Diabetes, Endocrinology, and Metabolism, Vanderbilt University Medical Center, Nashville, Tennessee 37232-8148, USA.
Root
Connie
C
Jagasia
Shubhada
S
D000328:Adult; D001323:Autoantibodies / Q000097:blood; D001379:Azathioprine / Q000008:administration & dosage; D005260:Female; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D007074:Immunoglobulin G / Q000097:blood; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D007328:Insulin / Q000008:administration & dosage; D007333:Insulin Resistance; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D011972:Receptor, Insulin / Q000276:immunology; D012074:Remission Induction
D001323:Autoantibodies; D007004:Hypoglycemic Agents; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D007328:Insulin; D011972:Receptor, Insulin; D001379:Azathioprine